COMMUNIQUÉS West-GlobeNewswire

JellyLean Claims Evaluated: Discover the Untold Truth About Jelly Lean Gelatin Trick Gummies Recipe for Weight Loss
17/04/2026
A 2026 informational overview addresses growing consumer interest in JellyLean gummies, the gelatin trick weight loss recipe trend, ingredient research context, pricing, and what adults searching for jelly lean [...]
Opticore Eye Group Unveils New Contact Lens Program in Riverside, CA for 2026
17/04/2026
Announces new contact lens program. Riverside, California, United States, April 17, 2026 (GLOBE NEWSWIRE) -- Opticore Eye Group, a leader in comprehensive eye care, is thrilled to announce the launch of its innovative [...]
New data demonstrates the unique scalability of Evaxion’s AI-Immunology™ platform in glioblastoma
17/04/2026
Data analysis conducted in collaboration with a leading academic medical center shows that AI ‑ Immunology™ enables vaccine design also for the deadly brain cancer, glioblastoma Uniquely, the platform can identify a [...]
Brazilian Wood Claims Evaluated: Discover the Male Enhancement Hardening Pill Truth by SuperNatural Man
17/04/2026
A 2026 informational report examining Brazilian Wood ingredient research, label disclosures, and consumer considerations for men evaluating male performance supplements by SuperNatural Man San Antonio, TX, April 17, [...]
Zentalis Pharmaceuticals To Present Azenosertib Preclinical Data in Triple-Negative Breast Cancer and Real-World Analysis of Unmet Need in Cyclin E1-Positive Ovarian Cancer at AACR 2026
17/04/2026
Preclinical data show encouraging activity of azenosertib combinations in ADC-resistant TNBC, supporting the potential for pipeline expansion beyond ovarian cancer Real-world data demonstrate Cyclin E1-positive ovarian [...]
Asgard Therapeutics to present preclinical data on lead asset AT-108, a personalized, off-the-shelf gene therapy, at AACR Annual Meeting 2026
17/04/2026
Asgard’s immunotherapy, AT-108, induces systemic, dose-dependent efficacy with broad tumor activity in preclinical studies and key biomarkers identified AT-108 combines the advantages of an off-the-shelf gene therapy [...]
NEXGEL Moves Forward Shareholder Update Call to Discuss Celularity Transaction on April 21st at 4:30 P.M. ET
17/04/2026
LANGHORNE, Pa., April 17, 2026 (GLOBE NEWSWIRE) -- NEXGEL, Inc. (“NEXGEL” or the “Company”) (NASDAQ: “NXGL”), a leading provider of healthcare, beauty, and over-the-counter (OTC) products including ultra-gentle, high- [...]
MiNK Therapeutics Reports Phase II Data on Immune Reprogramming and Durable Survival in PD-1 Refractory Gastroesophageal Cancer
17/04/2026
First study of agenT-797, botensilimab (BOT) and balstilimab (BAL) in gastroesophageal cancer shows disease control rate (DCR) in 77% of patients and long-term survival beyond 20 months in a subset of patients Induction [...]
Evaxion’s AI-Immunology™ platform demonstrates 86% vaccine target precision in phase 2 personalized cancer vaccine trial
17/04/2026
New phase 2 data from personalized cancer vaccine EVX-01 demonstrates a record-high rate of vaccine targets triggering a tumor-specific immune response The results reinforce that Evaxion’s pioneering AI platform, AI- [...]
Surgery Partners, Inc. Announces First Quarter 2026 Earnings Release Date and Conference Call Details
17/04/2026
BRENTWOOD, Tenn., April 17, 2026 (GLOBE NEWSWIRE) -- Surgery Partners, Inc. (NASDAQ:SGRY) ("Surgery Partners" or the "Company"), a leading short-stay surgical facility owner and operator, announced the Company will [...]
Dogecoin Cash, Inc. (OTCQB: DOGP) Announces Development Initiative for “Dogecoin Gold” Digital Asset Framework
17/04/2026
MESQUITE, NV, April 17, 2026 (GLOBE NEWSWIRE) -- Dogecoin Cash, Inc. (OTCQB: DOGP) (“DOGP” or the “Company”) today announced it is advancing the development of “Dogecoin Gold,” a proposed blockchain-based digital asset [...]
Genmab A/S Share Capital Reduction
17/04/2026
Company Announcement COPENHAGEN, Denmark; April 17, 2026 – Genmab A/S (Nasdaq: GMAB) At Genmab A/S’ Annual General Meeting on March 19, 2026, it was decided to reduce the Company’s share capital with nominally DKK 1,900 [...]
Yuhua Zhang, PhD, Named Chairholder of the Carolyn and Chuck Miller Endowed Chair for Vision Research
17/04/2026
PASADENA, Calif., April 17, 2026 (GLOBE NEWSWIRE) -- Doheny Eye Institute , one of the nation’s leading vision research institutions for nearly 80 years, named Yuhua Zhang, PhD, chairholder of the Carolyn and Chuck [...]
SRx Health Solutions and EMJX Issue Letter to Shareholders from Eric M. Jackson
17/04/2026
EMJ Crypto Technologies (EMJX) Founder and CEO Mr. Jackson provides update on operational progress and timing of proposed merger between SRx Health Solutions and EMJX NORTH PALM BEACH, Fla., April 17, 2026 (GLOBE [...]
Lexicon to Present Data at the American Academy of Neurology (AAN) Annual Meeting
17/04/2026
Oral presentation highlights additional data from PROGRESS Phase 2b study of pilavapadin supporting selection of 10mg as optimal dose for Phase 3 development in DPNP New data on spasticity further validates the broader [...]
Lyra Therapeutics, Inc. Announces Intention to Voluntarily File Form 25 for Delisting from Nasdaq and Subsequent Deregistration with the SEC
17/04/2026
WATERTOWN, Mass., April 17, 2026 (GLOBE NEWSWIRE) -- Lyra Therapeutics, Inc. (the "Company") today announced its intention to voluntarily file a Form 25 Notification of Delisting with the U.S. Securities and Exchange [...]
Cogent Biosciences Announces Poster Presentations at the American Association for Cancer Research (AACR) Annual Meeting 2026
17/04/2026
– Updated presentation on Cogent’s potent pan-KRAS(ON) inhibitor, CGT1263, showcasing its selectivity profile which could lead to reduction in skin toxicity associated with multi-RAS inhibitors – Updated presentation on [...]
Upstream Bio to Present New Data from Phase 2 VIBRANT Trial of Verekitug at the ATS 2026 International Conference
17/04/2026
WALTHAM, Mass., April 17, 2026 (GLOBE NEWSWIRE) -- Upstream Bio, Inc. (Nasdaq: UPB), a clinical-stage company developing treatments for inflammatory diseases, with an initial focus on severe respiratory disorders, today [...]
BioXcel Therapeutics Announces Virtual Event to Discuss Commercial Launch Plan Based on Market Opportunity Assessment for IGALMI® in the At-Home Setting
17/04/2026
Live event to be held on Thursday, April 23, at 2:00 p.m. ET Company focused on advancing launch strategy ahead of November 14 PDUFA target action date NEW HAVEN, Conn., April 17, 2026 (GLOBE NEWSWIRE) -- BioXcel [...]

Pages